Vaccine Market Access Strategies and Challenges

This white paper discusses the complexities and challenges associated with vaccine market access, particularly focusing on the role of National Immunization Technical Advisory Groups (NITAGs) and health technology assessments (HTAs). It outlines the significant differences in market access pathways for vaccines compared to other pharmaceuticals, emphasizing the need for a strategic approach to expedite access. The document presents the '100 days to vaccine market access' initiative aimed at addressing the hurdles faced by manufacturers and improving patient access to vaccines. It details the decision-making processes involving NITAGs, which are crucial in guiding vaccine recommendations, and highlights the barriers that can delay access, such as clinical data issues and economic factors. The paper also underscores the consequences of delayed vaccine availability, particularly in the context of the COVID-19 pandemic, where access disparities have led to significant clinical and economic impacts. Overall, it stresses the importance of understanding these dynamics for effective vaccine development and distribution.